Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction.

van Dijk A, Krijnen PA, Vermond RA, Pronk A, Spreeuwenberg M, Visser FC, Berney R, Paulus WJ, Hack CE, van Milligen FJ, Niessen HW.

Apoptosis. 2009 Jun;14(6):753-63. doi: 10.1007/s10495-009-0350-x.

PMID:
19421861
2.

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GG, Houser JE, Qureshi IZ, Ownby ED, Gustini E, Biasucci LM, Severino A, Capogrossi MC, Vetrovec GW, Crea F, Baldi A, Kukreja RC, Dobrina A.

Circulation. 2008 May 20;117(20):2670-83. doi: 10.1161/CIRCULATIONAHA.107.740233. Epub 2008 May 12.

3.

Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis.

Matsushita K, Iwanaga S, Oda T, Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S.

Lab Invest. 2005 Oct;85(10):1210-23.

4.

Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis.

Sipkens JA, Krijnen PA, Meischl C, Cillessen SA, Smulders YM, Smith DE, Giroth CP, Spreeuwenberg MD, Musters RJ, Muller A, Jakobs C, Roos D, Stehouwer CD, Rauwerda JA, van Hinsbergh VW, Niessen HW.

Apoptosis. 2007 Aug;12(8):1407-18.

5.

Application of zinc-bis-(DL-hydrogensaspartate) does not reduce apoptotic cell death in myocardial infarction in the rat heart.

Schwarz ER, Tussing T, Skobel E, Klosterhalfen B, Domanski D, Fuess JE.

J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):215-21. doi: 10.1177/1074248409340159. Epub 2009 Jul 15.

PMID:
19605571
6.

Caspases in myocardial infarction.

Zidar N, Jera J, Maja J, Dusan S.

Adv Clin Chem. 2007;44:1-33. Review.

PMID:
17682338
7.

Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.

Fujioka D, Saito Y, Kobayashi T, Yano T, Tezuka H, Ishimoto Y, Suzuki N, Yokota Y, Nakamura T, Obata JE, Kanazawa M, Kawabata K, Hanasaki K, Kugiyama K.

Circulation. 2008 Jun 10;117(23):2977-85. doi: 10.1161/CIRCULATIONAHA.107.743997. Epub 2008 May 27.

8.

Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.

Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G, Protter AA.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1972-7. Epub 2006 Jun 2.

9.
10.

Oxidized phosphatidylcholine stimulates activity of secretory phospholipase A2 group IIA and abolishes sphingomyelin-induced inhibition of the enzyme.

Korotaeva AA, Samoilova EV, Piksina GF, Prokazova NV.

Prostaglandins Other Lipid Mediat. 2010 Feb;91(1-2):38-41. doi: 10.1016/j.prostaglandins.2009.12.004. Epub 2010 Jan 4.

PMID:
20044023
11.

Opposite effects of native and oxidized lipoproteins on the activity of secretory phospholipase A(2) group IIA.

Korotaeva AA, Samoilova EV, Pirkova AA, Ameliushkina VA, Prokazova NV, Tkachuk VA, Chazov EI.

Prostaglandins Other Lipid Mediat. 2009 Nov;90(1-2):37-41. doi: 10.1016/j.prostaglandins.2009.07.004. Epub 2009 Jul 30.

PMID:
19647092
12.

CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion.

Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S.

J Mol Cell Cardiol. 2009 May;46(5):612-20. doi: 10.1016/j.yjmcc.2008.12.014. Epub 2009 Jan 7.

PMID:
19162037
13.

Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex.

Xiang Y, Chen L, Liu H, Liu X, Wei X, Sun B, Wang T, Zhang X.

PLoS One. 2013 Oct 9;8(10):e77909. doi: 10.1371/journal.pone.0077909. eCollection 2013.

14.
15.

HL-1 mouse cardiomyocyte injury and death after simulated ischemia and reperfusion: roles of pH, Ca2+-independent phospholipase A2, and Na+/H+ exchange.

Andersen AD, Poulsen KA, Lambert IH, Pedersen SF.

Am J Physiol Cell Physiol. 2009 May;296(5):C1227-42. doi: 10.1152/ajpcell.00370.2008. Epub 2009 Mar 4.

16.

Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction.

Nijmeijer R, Meuwissen M, Krijnen PA, van der Wal A, Piek JJ, Visser CA, Hack CE, Niessen HW.

Eur J Clin Invest. 2008 Apr;38(4):205-10. doi: 10.1111/j.1365-2362.2008.01933.x.

PMID:
18339001
17.
18.

Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis.

Ibeas E, Fuentes L, Martín R, Hernández M, Nieto ML.

Cardiovasc Res. 2009 Jan 1;81(1):54-63. doi: 10.1093/cvr/cvn234. Epub 2008 Aug 28.

PMID:
18755682
19.

Secretory phospholipase A2 inhibitor PX-18 preserves microvascular reactivity after cerebral ischemia in piglets.

Domoki F, Zimmermann A, Lenti L, Tóth-Szuki V, Pardeike J, Müller RH, Bari F.

Microvasc Res. 2009 Sep;78(2):212-7. doi: 10.1016/j.mvr.2009.06.004. Epub 2009 Jun 22.

PMID:
19555699
20.

Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium.

Wei-hua L, Chang-qing S, Qiang X, Rong W, Kai-min L.

Arch Med Res. 2009 Feb;40(2):67-72. doi: 10.1016/j.arcmed.2008.12.006.

PMID:
19237014

Supplemental Content

Support Center